GlassScriptPhysician profile
Noel L Helmic
NPI 1447264858
$5,545.10
in general payments reported to CMS, 2019-2025
20 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $497 · 2022: $1,581 · 2023: $1,737 · 2024: $1,268 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,467.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,417.95 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $482.93 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Corium, LLC | $399.12 | 2021-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $387.74 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $358.63 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $325.06 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $306.38 | 2021-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $269.49 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $247.24 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $236.94 | 2022-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $232.41 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $216.36 | 2022-2025 | Rexulti |
| Tempus Ai, INC | $173.61 | 2024 | |
| Almatica Pharma LLC | $133.81 | 2022-2024 | Loreev Xr, Sertraline Hcl, Citalopram |
| Axsome Therapeutics, INC. | $105.34 | 2024-2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $88.10 | 2024-2025 | Xelstrym |
| Vanda Pharmaceuticals INC. | $55.53 | 2023-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $53.01 | 2022-2023 | Trintellix |
| Collegium Pharmaceutical, INC. | $41.25 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $14.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Helmic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.